Amgen (NASDAQ:AMGN) Stock Sold by Rep. David Taylor

Representative David Taylor (Republican-Ohio) recently sold shares of Amgen Inc. (NASDAQ:AMGN). In a filing disclosed on November 12th, the Representative disclosed that they had sold between $1,001 and $15,000 in Amgen stock on November 3rd. The trade occurred in the Representative’s “DAVID TAYLOR TRUST > SARDINIA READY MIX 401(K) – DAVE” account.

Representative David Taylor also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Home Depot (NYSE:HD) on 11/5/2026.
• Sold $1,001 – $15,000 in shares of Procter & Gamble (NYSE:PG) on 11/5/2026.
• Purchased $1,001 – $15,000 in shares of Broadcom (NASDAQ:AVGO) on 11/5/2026.
• Purchased $1,001 – $15,000 in shares of Lam Research (NASDAQ:LRCX) on 11/5/2026.
• Sold $1,001 – $15,000 in shares of Eli Lilly and Company (NYSE:LLY) on 11/3/2026.
• Purchased $1,001 – $15,000 in shares of Eaton (NYSE:ETN) on 11/3/2026.
• Sold $1,001 – $15,000 in shares of Kroger (NYSE:KR) on 11/3/2026.
• Purchased $1,001 – $15,000 in shares of AT&T (NYSE:T) on 11/3/2026.
• Purchased $1,001 – $15,000 in shares of Alphabet (NASDAQ:GOOGL) on 11/3/2026.
• Sold $1,001 – $15,000 in shares of Visa (NYSE:V) on 11/3/2026.

Amgen Trading Down 0.3%

Amgen stock traded down $1.39 during mid-day trading on Friday, hitting $465.67. The company’s stock had a trading volume of 2,122,101 shares, compared to its average volume of 2,720,013. The firm has a market capitalization of $251.89 billion, a PE ratio of 27.01, a price-to-earnings-growth ratio of 3.25 and a beta of 0.43. Amgen Inc. has a 1 year low of $312.39 and a 1 year high of $483.99. The company has a current ratio of 1.48, a quick ratio of 1.20 and a debt-to-equity ratio of 3.60. The stock’s fifty day moving average is $425.31 and its two-hundred day moving average is $381.17.

Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, November 3rd. The medical research company reported $6.45 EPS for the quarter, beating analysts’ consensus estimates of $5.79 by $0.66. Amgen had a return on equity of 114.99% and a net margin of 24.14%. The company had revenue of $10.37 billion for the quarter, compared to the consensus estimate of $10.07 billion. During the same quarter in the previous year, the business earned $5.64 earnings per share. The company’s revenue for the quarter was up 8.5% on a year-over-year basis. On average, analysts anticipate that Amgen Inc. will post 23.37 EPS for the current year.

Amgen Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 11th. Investors of record on Friday, November 20th will be given a $2.52 dividend. This represents a $10.08 annualized dividend and a yield of 2.2%. The ex-dividend date is Friday, November 20th. Amgen’s dividend payout ratio is presently 58.47%.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on AMGN shares. Weiss Ratings raised shares of Amgen from a “buy (b)” rating to a “buy (b+)” rating in a research note on Thursday, October 8th. BMO Capital Markets reduced their price target on shares of Amgen from $450.00 to $415.00 and set a “market perform” rating on the stock in a research note on Monday, October 12th. UBS Group boosted their price target on shares of Amgen from $470.00 to $530.00 and gave the company a “buy” rating in a research note on Wednesday, November 4th. Scotiabank upped their price objective on shares of Amgen from $500.00 to $530.00 and gave the stock a “sector outperform” rating in a report on Wednesday, November 4th. Finally, Robert W. Baird upped their price objective on shares of Amgen from $215.00 to $230.00 and gave the stock an “underperform” rating in a report on Wednesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, eighteen have assigned a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $424.66.

Institutional Trading of Amgen

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Jump Financial LLC acquired a new stake in shares of Amgen during the third quarter worth about $14,833,000. Perennial Investment Advisors LLC boosted its stake in shares of Amgen by 20.5% in the third quarter. Perennial Investment Advisors LLC now owns 3,731 shares of the medical research company’s stock valued at $1,573,000 after purchasing an additional 635 shares during the period. L2 Asset Management LLC grew its holdings in shares of Amgen by 8.7% in the third quarter. L2 Asset Management LLC now owns 33,958 shares of the medical research company’s stock valued at $14,314,000 after purchasing an additional 2,717 shares in the last quarter. FLC Capital Advisors grew its holdings in shares of Amgen by 14.4% in the third quarter. FLC Capital Advisors now owns 2,386 shares of the medical research company’s stock valued at $1,006,000 after purchasing an additional 300 shares in the last quarter. Finally, Pathstone Holdings LLC grew its holdings in shares of Amgen by 3.1% in the third quarter. Pathstone Holdings LLC now owns 99,043 shares of the medical research company’s stock valued at $41,748,000 after purchasing an additional 3,017 shares in the last quarter. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Amgen News Summary

These are some of the AMGN news items that stood out recently:

• Positive Sentiment: Argus raised its price target to $515 from $460 and maintained a buy rating, signaling further upside in its view. Article
• Neutral Sentiment: A Trefis article examines Amgen’s valuation relative to peers, but the provided summary does not include its conclusion. Article
• Negative Sentiment: One report puts the consensus price target at $422.76, below the recent reference price of $465.67; that gap could temper sentiment despite Argus’ more bullish forecast. Article

About Representative Taylor

David Taylor (Republican Party) is a member of the U.S. House, representing Ohio’s 2nd Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Taylor (Republican Party) ran for election to the U.S. House to represent Ohio’s 2nd Congressional District. He won in the general election on November 5, 2024.

David Taylor graduated from Amelia High School. Taylor earned degrees from Miami University (Ohio) and the University of Dayton School of Law. Taylor’s career experience includes working as an attorney and as a businessman at Sardinia Ready Mix, Inc.

Amgen Company Profile

Amgen is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious illnesses. Its research and product portfolio span areas including cancer, cardiovascular disease, inflammation, bone health and rare diseases. The company’s medicines include Enbrel, Prolia, Xgeva and Repatha. Amgen serves patients and healthcare providers in the United States and markets its products internationally. Founded in 1980 and headquartered in Thousand Oaks, California, Amgen is led by Robert A. Bradway, who has served as its chief executive officer since 2012.